Search clinical trials for: Antivirus

Total 47 results

Fujian Maternity and Child Health Hospital

Recruiting

Prognostic Study of HPV Virus Integration in Women With HSIL

HPV Infection | Virus Integration | HSIL, High Grade Squamous Intraepithelial Lesions

China
Southeast University, China
Hohhot First Hospital, Hohhot, Inner Mongolia, China

Recruiting

The Efficacy of Azvudine and Paxlovid in High-risk Patients With COVID-19: A Prospective Randomized Controlled Trial

SARS-CoV-2 Infection

China
Institut Pasteur
National Institute of Hygiene and Epidemiology, Vietnam; ANRS, Emerging Infectious...

Not yet recruiting

Evaluation of HCV Care and Treatment for HIV-HCV Co-infected Patients in Decentralised Areas in Vietnam (MOVIDA-Hep2)

HIV Infection | Hepatitis C Infection

Vietnam
Fujian Maternity and Child Health Hospital

Recruiting

Research About Impact of HPV Integration on the Prognosis of Women With Persistent HR-HPV Infection

HPV Infection | LSIL, Low-Grade Squamous Intraepithelial Lesions | HSIL, High-Grade Squamous Intraepithelial Lesions | Virus Integration

China
Fujian Maternity and Child Health Hospital

Recruiting

Effect of HPV Integration on Prognosis of Young Women With CIN2 in China

Cervical Intraepithelial Neoplasia | HPV Infection | Virus Integration | HSIL, High Grade Squamous Intraepithelial Lesions

China
Sun Yat-sen University

Not yet recruiting

Prospective Cohort Study on Prognosis of Patients With Hepatitis B/C

Hepatitis B | Hepatitis C
ANRS, Emerging Infectious Diseases

Completed

DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C) (DRIVE-C)

Hepatitis C | Viral Hepatitis C | Drug Use

Vietnam
Nutrin GmbH

Completed

To Check Effectiveness of Medistus Antivirus Lozenges for Cough

Pharyngitis | Sore Throat | Throat Infection

India
AbbVie

Completed

A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530

Hepatitis C

United States, Australia, Belgium, Canada, Germany, New Zealand, Puerto Rico, United Kingdom
Gilead Sciences

Completed

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection

Hepatitis C Virus Infection

United States, Puerto Rico
Gilead Sciences

Completed

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy

Hepatitis C Virus Infection

Egypt
Gilead Sciences

Completed

Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects

Chronic Hepatitis C Virus

United States
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection (ION-2)

Chronic Hepatitis C Virus

United States
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection

Hepatitis C Virus Infection

Estonia, Russian Federation
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV

Chronic Hepatitis C Virus

United States, France, Italy, United Kingdom, Germany, Spain, Puerto Rico
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection

Hepatitis C Virus Infection

Egypt
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection

Hepatitis C Virus Infection

Canada
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)

Chronic Hepatitis C Virus

United States
Jean-Pierre Van geertruyden
University Hospital, Antwerp; University of Kinshasa

Completed

Impact of AV2 Antiviral Drug on the Treatment of HPV-associated Lesions of the Uterine Cervix (KINVAV)

Papillomavirus Infections | Uterine Cervical Dysplasia

Congo, The Democratic Republic of the
Gilead Sciences

Completed

Gilead Sustained Virologic Response (SVR) Registry

Hepatitis C, Chronic

United States, Spain, Netherlands, France, Australia, Canada, Italy, Germany, New Zealand, Belgium, Sweden, United Kingdom, Estonia, Puerto Rico, Austria, Poland, Czechia
Gilead Sciences

Completed

A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response

Hepatitis C, Chronic

United States, Spain, Australia, Netherlands, Italy, New Zealand, Germany, United Kingdom, France, Sweden, Canada, Estonia, Poland, Puerto Rico, Austria, Czechia
AbbVie (prior sponsor, Abbott)

Completed

A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study

Hepatitis C
National Institute of Allergy and Infectious Diseases...

Completed

Study of A Combination Pill With GS-7977 and GS-5885 for Hepatitis C in People With HIV

Hepatitis C | HIV

United States
Eastern Hepatobiliary Surgery Hospital

Completed

Efficacy and Significance of Antiviral Therapy for Unresectable Hepatitis B Virus-related Primary Liver Cancer

Primary Liver Cancer

China
The Affiliated Hospital of the Chinese Academy...

Unknown

Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors

Neuroendocrine Tumors

China
The Affiliated Hospital of the Chinese Academy...
Beijing Genova Biotech Company, Ltd.

Completed

Recombinant Anti-tumor and Anti-virus Protein for Injection in Treatment of Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
The Affiliated Hospital of the Chinese Academy...

Unknown

Recombinant Anti-tumor and Anti-virus Protein for Injection Plus Xeloda in Treatment of Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Gilead Sciences

Completed

Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies

Chronic Hepatitis C

United States, Germany, Australia, United Kingdom, France, Netherlands, Canada, New Zealand, Italy, Poland, Austria, Estonia, Spain, Sweden, Puerto Rico, Czech Republic
Gilead Sciences

Completed

Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection

Hepatitis C Virus

Egypt
National Institute of Allergy and Infectious Diseases...

Completed

GS-7977 With Ribavirin for Hepatitis C (SPARE)

Hepatitis C

United States
Gilead Sciences

Completed

Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3

Hepatitis C

United States
Gilead Sciences

Completed

Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION) (FUSION)

Chronic Hepatitis C

United States, Canada, New Zealand, Puerto Rico
Gilead Sciences

Completed

Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon (POSITRON)

Chronic Hepatitis C

United States, Canada, New Zealand, Puerto Rico, Australia
Gilead Sciences

Completed

Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection (NEUTRINO)

Chronic Hepatitis C

United States, Puerto Rico
Gilead Sciences

Completed

Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection

Hepatitis C, Chronic

United States, Puerto Rico
Gilead Sciences

Completed

A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Hepatitis C, Chronic

United States, United Kingdom, France, Germany, Netherlands, Belgium, Austria, Poland
Gilead Sciences

Completed

GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus

Hepatitis C, Chronic

United States, Puerto Rico, Australia
Gilead Sciences

Completed

A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Chronic Hepatitis C Infection

United States, Spain, United Kingdom, Canada, Germany, France, Austria, Poland, Belgium, Czech Republic, Italy
Gilead Sciences

Approved for marketing

Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C

Post-transplant Hepatitis C
Gilead Sciences

Completed

GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection

Chronic Genotype 1a or 1b HCV Infection

United States, Canada, Puerto Rico
Gilead Sciences

Completed

GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection

Hepatitis C, Chronic

United States, Puerto Rico
Gilead Sciences

Completed

GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection

Hepatitis C, Chronic

United States, Germany
Sun Yat-sen University

Unknown

Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma

Recurrence | Hepatocellular Carcinoma | Hepatitis B Virus

China
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I/II Study of the Combination of Azidothymidine and Interleukin-2 (IL-2) in the Treatment of HIV-Infected Patients

HIV Infection

United States
National Cancer Institute (NCI)

Completed

A Randomized Pilot Study for the Treatment of AIDS or AIDS Related Complex With an Alternating or Simultaneous Combination Regimen of AZT and 2',3'-Dideoxyinosine

Acquired Immunodeficiency Syndrome | AIDS-Related Complex

United States
National Institute of Allergy and Infectious Diseases...

Completed

Drug Interactions Among Anti-HIV Agents

HIV Infection

United States
Medtronic Cardiac Rhythm and Heart Failure

Completed

SAVEPACe - Search AV Extension and Managed Ventricular Pacing for Promoting Atrio-Ventricular Conduction (SAVEPACe)

Atrial Fibrillation | Bradycardia | Ventricular Dysfunction | Heart Failure, Congestive | Sick Sinus Syndrome

United States, Canada

3

Subscribe